Low CFB expression is independently associated with poor overall and disease‑free survival in patients with lung adenocarcinoma

He,Chenglu; Li,Ya; Zhang,Ruixian; Chen,Jing; Feng,Xingxing; Duan,Yong

doi:10.3892/ol.2021.12739

Low CFB expression is independently associated with poor overall and disease‑free survival in patients with lung adenocarcinoma

Authors:
- Chenglu He
- Ya Li
- Ruixian Zhang
- Jing Chen
- Xingxing Feng
- Yong Duan
View Affiliations

Affiliations: Yunnan Key Laboratory of Laboratory Medicine, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China, Department of Environment-Related Health, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan 650034, P.R. China, Health Management Center, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China, Department of Clinical Laboratory, Kunming Children's Hospital, Kunming, Yunnan 650228, P.R. China
Published online on: April 19, 2021 https://doi.org/10.3892/ol.2021.12739
Article Number: 478
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Complement factor B (CFB) serves a pivotal role in the alternative signaling pathway of the complement system and exerts a key role in the labelling of target particles, resulting from effective clearance of the target. The present study aimed to investigate the association between low expression levels of CFB and the clinical features and survival status of patients with lung adenocarcinoma (LUAD). Patient data were based on RNA‑sequencing and clinical data from The Cancer Genome Atlas database. All patients were divided into two groups based on the median expression of CFB. Kaplan‑Meier curve and univariate Cox regression analyses were used to investigate the association between CFB and survival status. Gene set enrichment analysis was used to examine the effects of CFB expression on signaling pathway impairment. Furthermore, reverse transcription‑quantitative PCR (RT‑qPCR) and western blotting were used to verify the relative expression levels of CFB in LUAD tissues. The data revealed that residual tumor classification, Karnofsky performance score and cancer stage were associated with overall survival, and that Karnofsky performance score and stage were associated with disease‑free survival. The results demonstrated that high expression levels of CFB were associated with increased patient overall and disease‑free survival according to both continuous and categorical models. The results of multivariate analysis identified that high expression levels of CFB were associated with increased overall and disease‑free survival according to both the continuous model [hazard ratio (HR), 0.48; 95% confidence interval (95% CI), 0.25‑0.93; P=0.029 for overall survival; HR, 0.29; 95% CI, 0.15‑0.59; P=0.001 for disease‑free survival] and the categorical model (HR, 0.46; 95% CI, 0.22‑0.93; P=0.031 for overall survival; HR, 0.25; 95% CI, 0.12‑0.55; P=0.001 for disease‑free survival) after adjusting for corresponding covariates (residual tumour classification, Karnofsky performance score and stage). Furthermore, the results of both RT‑qPCR and western blotting indicated that the relative mRNA and protein expression levels of CFB in lung tumor tissues were downregulated compared with those in adjacent non‑tumor tissues. Collectively, the present results suggested that CFB expression was an independent predictor of overall and disease‑free survival in patients with LUAD.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Jackman DM and Johnson BE: Small-cell lung cancer. Lancet. 366:1385–1396. 2005. View Article : Google Scholar : PubMed/NCBI
3	Li C and Lu H: Adenosquamous carcinoma of the lung. OncoTargets Ther. 11:4829–4835. 2018. View Article : Google Scholar : PubMed/NCBI
4	Scheff RJ and Schneider BJ: Non-small-cell lung cancer: treatment of late stage disease: chemotherapeutics and new frontiers. Semin Intervent Radiol. 30:191–198. 2013. View Article : Google Scholar : PubMed/NCBI
5	Yu HA, Paz-Ares LG, Yang JC, Lee KH, Garrido P, Park K, Kim JH, Lee DH, Mao H, Wijayawardana SR, et al: Phase I study of the efficacy and safety of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant non-small cell lung cancer. Clin Cancer Res. 27:992–1002. 2021. View Article : Google Scholar : PubMed/NCBI
6	Liu Y, Gao GF, Minna JD, Williams NS and Westover KD: Loss of wild type KRAS in KRASMUT lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors. Lung Cancer. 153:73–80. 2021. View Article : Google Scholar : PubMed/NCBI
7	Denisenko TV, Budkevich IN and Zhivotovsky B: Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 9:1172018. View Article : Google Scholar : PubMed/NCBI
8	Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA and Parsa AT: Cancer and the complement cascade. Mol Cancer Res. 8:1453–1465. 2010. View Article : Google Scholar : PubMed/NCBI
9	Gros P, Milder FJ and Janssen BJ: Complement driven by conformational changes. Nat Rev Immunol. 8:48–58. 2008. View Article : Google Scholar : PubMed/NCBI
10	Kleczko EK, Kwak JW, Schenk EL and Nemenoff RA: Targeting the complement pathway as a therapeutic strategy in lung cancer. Front Immunol. 10:9542019. View Article : Google Scholar : PubMed/NCBI
11	Walport MJ: Complement. First of two parts. N Engl J Med. 344:1058–1066. 2001. View Article : Google Scholar : PubMed/NCBI
12	Walport MJ: Complement. Second of two parts. N Engl J Med. 344:1140–1144. 2001. View Article : Google Scholar : PubMed/NCBI
13	Lee MJ, Na K, Jeong SK, Lim JS, Kim SA, Lee MJ, Song SY, Kim H, Hancock WS and Paik YK: Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma. J Proteome Res. 13:4878–4888. 2014. View Article : Google Scholar : PubMed/NCBI
14	Low HP, Tiwari A, Janjanam J, Qiu L, Chang CI, Strohsnitter WC, Norwitz ER, Tam SW, Evans JE, Green KM, et al: Screening preeclamptic cord plasma for proteins associated with decreased breast cancer susceptibility. Genomics Proteomics Bioinformatics. 11:335–344. 2013. View Article : Google Scholar : PubMed/NCBI
15	Byrne SN, Hammond KJ, Chan CY, Rogers LJ, Beaugie C, Rana S, Marsh-Wakefield F, Thurman JM and Halliday GM: The alternative complement component factor B regulates UV-induced oedema, systemic suppression of contact and delayed hypersensitivity, and mast cell infiltration into the skin. Photochem Photobiol Sci. 14:801–806. 2015. View Article : Google Scholar : PubMed/NCBI
16	Andoh A, Fujiyama Y, Sakumoto H, Uchihara H, Kimura T, Koyama S and Bamba T: Detection of complement C3 and factor B gene expression in normal colorectal mucosa, adenomas and carcinomas. Clin Exp Immunol. 111:477–483. 1998. View Article : Google Scholar : PubMed/NCBI
17	Suman S, Basak T, Gupta P, Mishra S, Kumar V, Sengupta S and Shukla Y: Corrigendum to ‘Quantitative proteomics revealed novel proteins associated with molecular subtypes of breast cancer’ [Journal of Proteomics 148, (2016) 183–193]. J Proteomics. 208:1035072019. View Article : Google Scholar : PubMed/NCBI
18	Kwak JW, Laskowski J, Li HY, McSharry MV, Sippel TR, Bullock BL, Johnson AM, Poczobutt JM, Neuwelt AJ, Malkoski SP, et al: Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Res. 78:143–156. 2018. View Article : Google Scholar : PubMed/NCBI
19	Azam F, Latif MF, Farooq A, Tirmazy SH, AlShahrani S, Bashir S and Bukhari N: Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol. 12:728–736. 2019. View Article : Google Scholar : PubMed/NCBI
20	Barbetta C, Allgar V, Maddocks M, Ribeiro C, Wilcock A, Currow DC, Phillips J and Johnson MJ: Australia-modified Karnofsky Performance Scale and physical activity in COPD and lung cancer: an exploratory pooled data analysis. BMJ Support Palliat Care. Jun 11–2019.(Epub ahead of print). doi: 10.1136/bmjspcare-2019-001869. View Article : Google Scholar : PubMed/NCBI
21	Woodard GA, Jones KD and Jablons DM: Lung Cancer Staging and Prognosis. Cancer Treat Res. 170:47–75. 2016. View Article : Google Scholar : PubMed/NCBI
22	Wishart DS: Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 15:473–484. 2016. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K, Cramer K, Neel J, Bergeron J, Barile GR, et al AMD Genetics Clinical Study Group, : Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 38:458–462. 2006. View Article : Google Scholar : PubMed/NCBI
25	Colten HR: Biosynthesis of the MHC-linked complement proteins (C2, C4 and factor B) by mononuclear phagocytes. Mol Immunol. 19:1279–1285. 1982. View Article : Google Scholar : PubMed/NCBI
26	Canavese F, Botnari A, Andreacchio A, Marengo L, Samba A, Dimeglio A, Pereira B, Mansour M and Rousset M: Displaced tibial shaft fractures with intact fibula in children: Nonoperative management versus operative treatment with elastic stable intramedullary nailing. J Pediatr Orthop. 36:667–672. 2016. View Article : Google Scholar : PubMed/NCBI
27	Chen M, Muckersie E, Robertson M, Forrester JV and Xu H: Up-regulation of complement factor B in retinal pigment epithelial cells is accompanied by complement activation in the aged retina. Exp Eye Res. 87:543–550. 2008. View Article : Google Scholar : PubMed/NCBI
28	Ostvik AE, Granlund A, Gustafsson BI, Torp SH, Espevik T, Mollnes TE, Damås JK and Sandvik AK: Mucosal toll-like receptor 3-dependent synthesis of complement factor B and systemic complement activation in inflammatory bowel disease. Inflamm Bowel Dis. 20:995–1003. 2014.PubMed/NCBI
29	Potter BJ, Brown DJ, Watson A and Jewell DP: Complement inhibitors and immunoconglutinins in ulcerative colitis and Crohn's disease. Gut. 21:1030–1034. 1980. View Article : Google Scholar : PubMed/NCBI
30	Jiang DK, Ma XP, Yu H, Cao G, Ding DL, Chen H, Huang HX, Gao YZ, Wu XP, Long XD, et al: Genetic variants in five novel loci including CFB and CD40 predispose to chronic hepatitis B. Hepatology. 62:118–128. 2015. View Article : Google Scholar : PubMed/NCBI
31	Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et al TCGA Research Network, : Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 163:506–519. 2015. View Article : Google Scholar : PubMed/NCBI
32	Kim SH, Lee MJ, Hwang HK, Lee SH, Kim H, Paik YK and Kang CM: Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: A pilot study. Cancer Biomark. 24:335–342. 2019. View Article : Google Scholar : PubMed/NCBI
33	Lim LY, Tan GH, Zainuddin ZM, Fam XI, Goh EH, Syaris OS, Yahaya A and Singam P: Prospective evaluation of using multiparametric magnetic resonance imaging in cognitive fusion prostate biopsy compared to the standard systematic 12-core biopsy in the detection of prostate cancer. Urol Ann. 12:276–282. 2020. View Article : Google Scholar : PubMed/NCBI
34	Bauer D, Mazzio E, Hilliard A, Oriaku ET and Soliman KF: Effect of apigenin on whole transcriptome profile of TNFα-activated MDA-MB-468 triple negative breast cancer cells. Oncol Lett. 19:2123–2132. 2020.PubMed/NCBI